Product Description: Lefamulin (BC-3781) is an orally active antibiotic. Lefamulin inhibits protein synthesis by binding to the peptidyl transferase center of the 50S bacterial ribosome. Lefamulin has anti-inflammatory activity. Lefamulin can be used in the research of bacterial infections, such as bacterial pneumonia[1].
Applications: COVID-19-immunoregulation
Formula: C28H45NO5S
References: [1]Veve MP, et al. Lefamulin: Review of a Promising Novel Pleuromutilin Antibiotic. Pharmacotherapy. 2018 Sep;38(9):935-946. doi: 10.1002/phar.2166. Epub 2018 Aug 20./[2]Susanne Paukner, et al. Antimicrob Agents Chemother. 2018 Apr 26;62(5):e02380-17. /[3]Ken B Waites, et al. In Vitro Activities of Lefamulin and Other Antimicrobial Agents against Macrolide-Susceptible and Macrolide-Resistant Mycoplasma pneumoniae from the United States, Europe, and China. Antimicrob Agents Chemother. 2017 Jan 24;61(2):e02008-16. /[4]Michael Hafner, et al. Anti-inflammatory activity of lefamulin versus azithromycin and dexamethasone in vivo and in vitro in a lipopolysaccharide-induced lung neutrophilia mouse model. PLoS One. 2021 Sep 29;16(9): e0237659. https://pubmed.ncbi.nlm.nih.gov/34587166//[5]Wolfgang W Wicha, et al. Pharmacokinetics/pharmacodynamics of lefamulin in a neutropenic murine pneumonia model with Staphylococcus aureus and Streptococcus pneumonia. J Antimicrob Chemother. 2019 Apr 1;74(Suppl 3):iii11-iii18.
CAS Number: 1061337-51-6
Molecular Weight: 507.73
Compound Purity: 98.0
Research Area: Infection
Solubility: DMSO : 100 mg/mL (ultrasonic)
Target: Antibiotic;Bacterial
English
Deutsch
